Clinical Trial Update: Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy and safety of bimagrumab in patients after hip fracture surgery has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscular Wasting After Hip Fracture Surgery

Drugs mentioned

• Bimagrumab (bimagrumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Muscle Wasting (Atrophy) After Hip Fracture Surgery | Phase 2 | Status: COMPLETED | Results posted: 2020-08-19